## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.2% below STRENGTH zone (4.0-10.0%); PEG 4.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.06M) |
| Sells | 3 ($0.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.13 signals overvaluation risk, limited margin of safety. Forward P/E 29.4x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.13 |
| Forward P/E | 29.4 |
| Current P/E | 32.6 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.0% to -3.2% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.19% (CS: 30) | Weak |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $84.32
- **Stop Loss:** $80.56 (4.5% risk)
- **Target:** $88.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $11,130.24
- **Portfolio %:** 11.13%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*